Analytical Data
-
Gene name
CG-4
- Application
-
Alternative Names
(CG-beta-1)(Beta-conglycinin beta subunit)(allergen Gly m 5)
-
Species
Glycine max
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25974
-
Expression Region
24-439aa
-
Molecular Weight
55.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CG-4 recombinant protein has emerged as a significant focus in biomedical research due to its potential applications in immunology and gene therapy. Originally identified in the context of cellular signaling pathways, CG-4 is known to play a critical role in the development and function of the immune system. Studies have indicated that CG-4 interacts with specific receptors on immune cells, influencing their activation and proliferation. Researchers have aimed to harness this knowledge to create recombinant versions of the CG-4 protein to investigate its molecular mechanisms further. The recombinant protein serves as an essential tool for elucidating its functional properties, including its role in modulating immune responses. Additionally, CG-4 is being explored for its therapeutic potential in treating various diseases, such as autoimmune disorders and cancers, where immune regulation is crucial. The development of CG-4 recombinant protein not only aids in understanding immune mechanisms but also opens avenues for novel therapeutic strategies. As technology advances, the potential for CG-4-based interventions in disease treatment continues to gain interest, making it a promising target for future research initiatives.
